Resultats globals: 2 registres trobats en 0.01 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
6 p, 1.0 MB MYH9-related disease : it does exist, may be more frequent than you think and requires specific therapy / Fernandez-Prado, Raul (Red de Investigación Renal) ; Carriazo-Julio, Sol Maria (Red de Investigación Renal) ; Torra Balcells, Roser (Institut d'Investigació Biomèdica Sant Pau) ; Ortiz, Alberto (Red de Investigación Renal) ; Pérez-Gómez, Maria Vanessa (Red de Investigación Renal) ; Universitat Autònoma de Barcelona
In this issue of ckj, Tabibzadeh et al. report one of the largest series of patients with MYH9 mutations and kidney disease. The cardinal manifestation of MYH9-related disease is thrombocytopenia with giant platelets. [...]
2019 - 10.1093/ckj/sfz103
Clinical Kidney Journal, Vol. 12 (august 2019) , p. 488-493  
2.
9 p, 975.3 KB Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan : what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? / Fernández-Fernández, Beatriz (GEENDIAB) ; Fernandez-Prado, Raul (GEENDIAB) ; Górriz, Jose Luis (Hospital Clínic Universitari (València)) ; Martínez-Castelao, Alberto (Hospital Universitari de Bellvitge) ; Navarro-González, Juan F. (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ; Porrini, Esteban (Instituto de Tecnologías Biomédicas, Hospital Universitario de Canarias) ; Soler, María José (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ortiz, Alberto (GEENDIAB) ; Universitat Autònoma de Barcelona
In April 2019, two major Phase 3 randomized clinical trials were published that assessed primary renal outcomes in diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) tested an already available antidiabetic drug, canagliflozin, and the Study of Diabetic Nephropathy with Atrasentan (SONAR) tested a novel molecule, the endothelin-1 receptor blocker atrasentan, both on top of renin-angiotensin system blockade. [...]
2019 - 10.1093/ckj/sfz070
Clinical Kidney Journal, Vol. 12 (may 2019) , p. 313-321  

Vegeu també: autors amb noms similars
1 Fernandez-Prado, R.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.